INVESTORS

LISTENING TO THE MARKET NEEDS

DRUG DISCOVERY
We all know the high costs required to bring a drug to market and the high failure rate of potential compounds. In fact, the discovery of a new medicine requires more than 1,5 billion dollars and can take 12/15 years of research efforts. Research demands for new experimental models ensuring more predictive approaches, to better understand the fate of a drug before going into clinical trials.

RARE CELLS
Cells are not equally abundant, some of them are even rare, which makes it difficult to study them. Existing technologies already allow their isolation, selection and DNA analysis. What is missing, but definitely very much needed, is a laboratory tool allowing the performance of in-vivo imaging analyses (microscopy) of rare cells, taking into consideration that they are limited in number and difficult to manage.

EMBRIOLOGY
Despite the large number and the high costs of in-vitro fertilization treatments, only 1/3 of them are successful. It is proven that the first 4 days of embryo development are crucial; it is therefore necessary, since the very first stages, to cultivate embryos having the possibility to change and adapt biological conditions, as if they were developing in the mother’s apparatus. Monitoring embryo development through time-lapse imaging becomes equally essential to select the best ones to be then implanted.

IDEAS THAT CAN CHANGE THE WORLD

We have taken up the challenge to meet the needs of research for the development of new experimental models. Thanks to our CELLviewer technology, we provide laboratory equipment allowing the real-time 3D observation of cells in an in-vivo-like environment.

WHERE WE STAND NOW AND WHAT IS NEXT

Since 2013, we have collected 950k€ (500k€ and 450k€ from private and public sectors respectively). Today, we are an innovative start-up company, with a team of 7, working full time. The first prototype is ready and has raised great interest among the scientific community.

We need 700k€ more to develop a new line of product, get IP protection and go to market.

We are looking for people who believe in us and decide to contribute to our big challenge. If you want to be part of a great advancement in scientific research, we are looking for you.

FUNDS COLLECTED SO FAR

500k

From private sector

450k

From public grant

FURTHER NEEDED RESOURCES

700k

Current fundraising challenge

RETURN ON INVESTMENT

We have proven our technology to be able to activate automated, repeatable, effective, time and cost saving in-vitro research processes in many fields of applications.

Given the clear expression of interest of big market players (i.e. Olympus), we are considering an exit strategy soon. We expect a ROI of 15 to 40 by 2021.

ROI

WHO BELIEVED IN US

Costa-Luigi

Luigi Costa

CEO at Nordic Nanovector ASA, with over 20 years of experience in the pharmaceutical and biotech industry 

I have invested in CellDynamics for two reasons: the innovative technology with a promising potential to support research in biotech and the skilled team developing it.

Fracassi

Angelo Fracassi & Lorenzo Oreste Fracassi

Chairman and  CEO at DASIT Group leading company in the biotechnology and healthcare sector at Italian level

We’ve met CellDynamics’ team in 2015 and we’ve been favourably impressed with their project and the methods they used to carry it out. Their new system of colture and analysis of cells in suspension can lead to the creation of disruptive scenarios in both biomedical applications and in the development of new drugs.

BE PART OF OUR CHALLENGE